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Physical stress, including high temperatures, may damage the central metabolic nicotinamide nucleotide cofactors [NAD(P)H],
generating toxic derivatives [NAD(P)HX]. The highly conserved enzyme NAD(P)HX dehydratase (NAXD) is essential for intra-
cellular repair of NAD(P)HX. Here we present a series of infants and children who suffered episodes of febrile illness-induced
neurodegeneration or cardiac failure and early death. Whole-exome or whole-genome sequencing identified recessive NAXD
variants in each case. Variants were predicted to be potentially deleterious through in silico analysis. Reverse-transcription PCR
confirmed altered splicing in one case. Subject fibroblasts showed highly elevated concentrations of the damaged cofactors S-
NADHX, R-NADHX and cyclic NADHX. NADHX accumulation was abrogated by lentiviral transduction of subject cells with
wild-type NAXD. Subject fibroblasts and muscle biopsies showed impaired mitochondrial function, higher sensitivity to metabolic
stress in media containing galactose and azide, but not glucose, and decreased mitochondrial reactive oxygen species production.
Recombinant NAXD protein harbouring two missense variants leading to the amino acid changes p.(Gly63Ser) and p.(Arg608Cys)
were thermolabile and showed a decrease in Vmax and increase in KM for the ATP-dependent NADHX dehydratase activity. This is
the first study to identify pathogenic variants in NAXD and to link deficient NADHX repair with mitochondrial dysfunction. The
results show that NAXD deficiency can be classified as a metabolite repair disorder in which accumulation of damaged metabolites
likely triggers devastating effects in tissues such as the brain and the heart, eventually leading to early childhood death.
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Introduction
Metabolism is traditionally viewed as an efficient and pre-
cise system, supported by enzymes that are highly specific
for their substrate and the type of reaction through which
they convert the substrate. This view has been challenged
over recent years by the identification of a growing list of
enzymes that function to repair or remove metabolic side
products, the latter of which are generated by side reactions
of main metabolic enzymes. Metabolic side products can
also be produced intracellularly by unwanted spontaneous
chemical reactions. These non-canonical or ‘damaged’ me-
tabolites can inhibit key metabolic reactions if they are left
to accumulate. It is to precisely prevent the accumulation of
potentially toxic small molecules that all organisms of all
domains of life have most likely evolved a panoply of me-
tabolite repair systems (Linster et al., 2013; Van
Schaftingen et al., 2013).
The nicotinamide adenine dinucleotides (NAD) (reduced
form NADH, oxidized form NAD+ ) and nicotinamide ad-
enine dinucleotide phosphate (NADP) (reduced form
NADPH, oxidized form NADP+ ) have essential roles in
many cellular functions. NAD is involved in a series of
catabolic reactions and in mitochondrial energy production,
whereas NADP is a key component of numerous biosyn-
thetic processes as well as cellular antioxidant protection
systems (Ying, 2008; Houtkooper et al., 2010). The nico-
tinamide ring within these cofactors is prone to hydration,
forming NADHX or NADPHX, which can be present as R
or S epimers and which can further degrade irreversibly to
cyclic NAD(P)HX (Yoshida and Dave, 1975). NADHX can
be slowly produced from NADH by GAPDH (Rafter et al.,
1954); NAD(P)HX can also form spontaneously from the
normal reduced cofactors under ‘stress’ conditions such as
increased temperature or acidic pH (Rafter et al., 1954;
Yoshida and Dave, 1975). The damaged cofactors cannot
act as electron carriers and have been shown in vitro to
inhibit several key dehydrogenase enzymes (Yoshida and
Dave, 1975; Prabhakar et al., 1998). In Saccharomyces
cerevisiae, in vitro and in vivo evidence for an inhibitory
effect of NADHX on 3-phosphoglycerate oxidoreductase,
catalysing the initial step of the serine biosynthesis path-
way, has been obtained recently (Becker-Kettern et al.,
2018). Therefore, NAD(P)HX can be expected to be toxic
to cells, and detoxification by a metabolite repair system is
critical.
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The nicotinamide nucleotide repair system consists of two
partner enzymes: NAD(P)HX epimerase (NAXE, formerly
APOA1BP; OMIM: 608862), which converts R-NAD(P)HX
to S-NAD(P)HX, and NAD(P)HX dehydratase (NAXD, for-
merly CARKD; OMIM: 615910), which converts S-
NAD(P)HX back to NAD(P)H in an ATP-dependent
manner (Marbaix et al., 2011). Both these enzymes are tar-
geted to several subcellular compartments, including the mito-
chondrion (Marbaix et al., 2014). They also have a
ubiquitous tissue distribution (Marbaix et al., 2014) and are
conserved across all taxa (Marbaix et al., 2011). The presence
of the NAD(P)HX repair enzymes across all tissues and spe-
cies, combined with the central metabolic roles of the cofac-
tors that they function to preserve, suggest that the repair
system is critical to sustain life. More specifically, it can be
predicted that the brain, which has a very high and constant
demand for energy supply generated by mitochondria, would
be particularly vulnerable to impaired NAD(P)HX repair and
as such, the NAXE and NAXD enzymes would be critical to
support normal brain function. In apparent contradiction
with those predictions, however, knocking out NAD(P)HX
repair enzymes in other organisms such as yeast, bacteria
and plants, has so far only revealed subtle growth pheno-
types, if any, at least under standard growth conditions
(Breslow et al., 2008; Hillenmeyer et al., 2008; Nichols
et al., 2011; Colinas et al., 2014; Niehaus et al., 2014;
Becker-Kettern et al., 2018).
Recently, whole exome sequencing identified pathogenic
variants in the epimerase NAXE, which were associated with
cases of a lethal neurometabolic disorder of early childhood
(Kremer et al., 2016; Spiegel et al., 2016). In these subjects, it
appeared that episodes of febrile illness aggravated the
consequences of an already compromised metabolite repair
system, resulting in rapid neurological deterioration and de-
composition of other tissues with clinical observation of
ataxia, muscular hypotonia, respiratory insufficiency and/or
respiratory failure, nystagmusand skinmanifestations followed
by premature death. This provided the first cases of subjects
with pathogenic variants in a key enzyme of the nicotinamide
nucleotide repair pathway. Here we report on the first known
cases with pathogenic variants in the dehydratase NAXD.
Materials and methods
Full materials and methods are available in online
Supplementary material.
Subjects and variant analysis
All procedures were approved by human research ethics com-
mittees. Primary cultures of fibroblasts were established from
skin biopsies.
Mitochondrial analysis
Fibroblast extracts were analysed by immunoblotting using
antibodies against representative oxidative phosphorylation
(OXPHOS) subunits. The complex I and IV activity was deter-
mined using commercially available dipstick assays
(MitoSciences). Mitochondrial stress was induced by culturing
fibroblasts galactose media and determining cell growth rates.
Mitochondria reactive oxygen species production was mea-
sured by dihydroethidium fluorescence.
LC-MS analysis of NAD(H),
NADP(H) and damaged derivatives
Wild-type NAXD including the mitochondrial targeting signal
(mNAXD) or not (cNAXD starting at Met3) or a GFP control
construct was introduced into patient fibroblasts by lentiviral
delivery. Intracellular metabolites were extracted from cultured
fibroblasts and concentrations were measured with an HRAM-
RP-LC-MS (high resolution accurate mass reversed phase
liquid chromatography mass spectrometry) method compared
against chemically pure standards.
NADHX dehydratase activity assays
and thermostability testing
Missense variants were introduced into wild-type cNAXD and
proteins expressed and purified from a bacterial overexpres-
sion system as detailed in the Supplementary material. The
S-NADHX substrate was synthesized and purified as pre-
viously described (Becker-Kettern et al., 2018) and NAXD
enzyme kinetic properties determined using a spectrophoto-
metric assay (Marbaix et al., 2011). Protein thermostability
was tested by pre-incubation of purified protein at different
temperatures (30–47C).
Statistical analysis
Statistical analyses were carried out using either a two-tailed
Student’s t-test or one-way ANOVA corrected for multiple
comparisons as appropriate (GraphPad Prism

Software).
Error bars represent the standard deviation of the mean
[standard deviation (SD)]. A P-value50.05 was considered
to be statistically significant.
Data availability
Derived data supporting the findings of this study are available
from the corresponding author upon request.
Results
In the present study we report six unrelated individuals
with homozygous or compound heterozygous variants in
NAXD. The predominant clinical features included
repeated episodes of regression often triggered by episodes
of mild fever or infection, an infantile onset neurodegenera-
tive condition (Fig. 1A–M) and skin lesions (Fig. 1O and
P), ultimately leading to early death in all cases. The clinical
features of our NAXD subjects therefore resembled those
of the previously published cases of NAXE deficiency
(Table 1), and detailed clinical reports for all cases are
available in Supplementary material. The six subjects with
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Figure 1 Neuroimaging findings and skin manifestations in children with NAXDmutations. Brain MRI scans for Case 1 at the age of
3 years and 7 months, 3 months after normal MRI scans: (A) axial T2, (B) diffusion (DWI) and (C) coronal T2 FLAIR showed bilateral and
symmetrical T2 high signal and cytotoxic oedema of the basal ganglia and focal areas of cortical involvement in the temporal lobes. Progress MRI
after 3 weeks: (D) axial T2, (E) DWI and (F) coronal T2 FLAIR showed bilateral and symmetrical T2 high signal and cytotoxic oedema of the basal
ganglia persist with increasing areas of asymmetrical cortical involvement in the temporal lobes and frontal lobes. Follow-up MRI 3 years later:
(G) axial T2, (H) axial and (I) coronal T2 FLAIR showed generalized cerebral atrophy, most marked in the frontal lobes and basal ganglia with
exvacuo-dilatation of the lateral ventricles. The high signal is consistent with gliosis. Case 2 MRI (J–M) showed bilateral hyperintensity of striatal
nuclei, which remained unchanged in subsequent scans. Case 4 brain MRI (N) showed bilateral basal ganglia changes suggestive of a mitochondrial
disorder. Extensive skin lesions in Case 4 (O and P).
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NAXD variants were identified individually by whole
exome or whole genome sequencing as part of either inde-
pendent international gene discovery cohorts, National
Health Services diagnostic testing or through the
Genematcher/Matchmaker database (Philippakis et al.,
2015; Sobreira et al., 2015).
Sanger sequencing confirmed all variants identified
through next generation sequencing (Supplementary Fig.
1). The human NAXD gene is predicted to generate four
coding transcripts, leading to the expression of cytosolic,
mitochondrial and endoplasmic reticulum (ER) protein iso-
forms, as explained in detail in the Supplementary material
(see also Supplementary Figs 2 and 3). For initial interpre-
tation we focused on the most abundant transcript RefSeq
isoform c (NM_001242882.1; Supplementary Table 1)
whose existence is most strongly supported by EST
(expressed sequence tag) analysis and from which mito-
chondrial and cytosolic NAXD protein forms can be trans-
lated (Supplemental material). In silico analyses predicted
the variants to be pathogenic to each of the four NAXD
transcript isoforms, and affect the structure and function of
the NAXD protein (Supplementary Table 2, Supplementary
Figs 2 and 3). By HSF3 analysis (Desmet et al., 2009) the
splicing variant in Case 1 was predicted to lead to disrup-
tion of the wild-type donor site, which was confirmed by
RT-PCR studies, revealing aberrant splicing and skipping
of Exon 9 (Supplementary Fig. 4).
We then used patient fibroblasts to determine the intra-
cellular concentrations of NAD(P), NAD(P)H, S-
NAD(P)HX, R-NAD(P)HX and cyclic-NAD(P)HX using
HRAM RP-LC-MS with comparison against chemically
pure standards (Supplementary Fig. 5). We detected no
significant differences in NAD, NADH and NADP levels
between control and subject-derived fibroblasts (NADPH
levels were below the limit of quantification). Importantly,
the damaged cofactor derivatives S-NADHX, R-NADHX
and cyclic-NADHX were only detected in fibroblasts from
Cases 1, 2 and 4, but not in any of our control cell lines
(Fig. 2A and B). Quantification of these metabolites
revealed a similar level of accumulation of S-NADHX
and R-NADHX in Cases 1, 2 and 4 (Fig. 2C).
Interestingly the levels detected in Case 3 were much
lower than for Cases 1, 2 and 4 and only just above
the detection threshold for LC-MS analysis (Fig. 2B).
Lentiviral transduction with either the cytosolic
(cNAXD) or mitochondrial (mNAXD) wild-type NAXD
cDNA completely prevented the accumulation of any of
the NADHX derivatives in fibroblasts from Cases 1 and 2
(Fig. 2D) whereas a control GFP construct had no effect
(Fig. 2D).
To address whether mitochondrial function is affected by
NAXD deficiency in our subjects, we examined the expres-
sion of representative protein subunits of the mitochondrial
respiratory chain and enzyme activity of complexes I and
IV in fibroblasts from Cases 1 and 2. There was a marked
reduction in the expression of both NDUFB8 (complex I
membrane subunit) and COXII (complex IV subunit) in
Cases 1 and 2 compared to four paediatric control fibro-
blast extracts (Fig. 3A and Supplementary Fig. 6). We
found a significant reduction in cytochrome c oxidase activ-
ity in Cases 1 and 2 compared to controls (Fig. 3B), whilst
complex I NADH oxidation activity was not affected (data
not shown). Mitochondrial superoxide production revealed
a significant decrease in rotenone-inhibited complex I
superoxide production in both Cases 1 and 2 compared
to controls (Fig. 3C). There was a significant decrease in
the growth rate of fibroblasts in glucose-free, galactose-
azide medium to induce mitochondrial stress from Cases
1 and 2 compared to control fibroblasts (Fig. 3D).
The NAXD missense variants [p.(Arg308Cys) and
p.(Gly63Ser)] were introduced by site-directed mutagenesis
into human NAXD cDNA, then expressed and purified as
recombinant proteins. For the p.(Gly63Ser) variant, we
found a 3.4-fold decrease in Vmax and a 3.3-fold increase
in KM compared to the wild-type protein. For the
p.(Arg308Cys) variant, we determined a 2.5-fold decrease
in Vmax and a 2.2-fold increase in KM compared to wild-
type (Supplementary Table 3). Thermostability analyses of
recombinant NAXD revealed that both the p.(Gly63Ser)
and the p.(Arg308Cys) proteins lost enzymatic activity
Table 1 Clinical findings in individuals with variants in NAXD or NAXE
Clinical presentation NAXD cases (present study) NAXE (previously published)
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Spiegel et al.
(2016)
Kremer et al.
(2016)
Gender M F F M F F 3F, 2M 2F, 4M
Episodes of fever/illness prior to deterioration Y Ya Y Y Y Y 5/5 4/6 (2 unclear)
Neurodegeneration Y Y N Y ?b Y 5/5 4/6 (2 unclear)
Skin lesions Y Y N Y N Y Not reported 4/6
Cardiac presentation N N N N Y N Not reported 2/6c
Early death Y Y Yd Y Y Y 4/5 6/6
aFever was associated with some, but not all episodes of deterioration.
bAbnormal MRI scan.
cTwo NAXE patients died from cardiovascular failure.
dSibling had mild developmental delay, mild anaemia, recurrent episodes of fever, and died after an episode of vomiting and lethargy at 1 year 7 months. N = no; Y = yes.
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upon pre-incubation at temperatures higher than 30C
while the wild-type protein activity resisted exposure to
temperatures up to 47C (Fig. 3E). This thermolability
was most pronounced for the p.(Arg308Cys) variant,
with a more than 90% decrease in activity above 45C,
while for the p.(Gly63Ser) variant this same treatment
resulted in a 40% activity loss (Fig. 3E).
Discussion
Here we report on the first known pathogenic NAXD var-
iants, which affected six families, leading to a fever-induced
severe multisystem disease and death within the first decade
of life. To explore the consequences of NAXD deficiency,
quantification of NAD(P)HX metabolites revealed a similar
Figure 2 NADHX accumulation in subject fibroblasts and phenotypic rescue by lentiviral gene delivery of wild-type NAXD.
Representative examples of LC-MS extracted ion chromatograms of (A) S- and R-NADHX metabolites (XIC = 682.12) and (B) NADH and cyclic
NADHX (XIC = 664.11). The chromatograms clearly show peaks of S-, R- and cyclic NADHX in Cases 1 and 2, and not in a control. (C)
Quantitative results of the NADHX measurements after cultivation of fibroblasts from Cases 1–4 under standard conditions at 37C for 96 h.
Note that these metabolites were not detected in four control fibroblast lines. Data are mean  SD, n = 3. (D) Quantitative results of the
NADHX measurements in lentiviral-rescued cells. There was a clear accumulation of S-, R- and cyclic NADHX in Cases 1 and 2, independently of
transduction with GFP-only vectors. S-, R- and cyclic NADXH were not detected in control fibroblasts. Lentiviral gene rescue with either the
mNAXD or cNAXD construct completely prevented accumulation of S-, R- and cyclic NADHX in subject cells. Data are mean  SD, n = 3.
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level of accumulation of S-NADHX and R-NADHX in
Cases 1, 2 and 4 in the expected 60:40 S to R epimer
ratio (Marbaix et al., 2011). This was completely reversed
by lentiviral transduction with either cytosolic (cNAXD) or
mitochondrial (mNAXD) lentiviral constructs. Supposing
an intracellular fibroblast volume of 2 pl, the approximate
intracellular concentrations of S-NADHX (100–300 mM)
and R-NADHX (70–210 mM) were quantitatively similar
Figure 3 Mitochondrial impairment in NAXD subject fibroblasts and thermostability of recombinant NAXD protein variants.
(A) Mitochondrial OXPHOS proteins were separated by SDS-PAGE, probed for relative expression levels of key OXPHOS subunits by immu-
noblotting, and expression levels normalized to GAPDH as a loading control. There was a significant decrease in the expression of complex I and
complex IV proteins expression in Cases 1 and 2 compared to controls. (B) Mitochondrial OXPHOS enzyme activity was measured in cell
extracts by immunocapture dipstick assays. There was a significant decrease in complex IV activity [monoclonal antibodies (mAbs)/mg protein] in
Cases 1 and 2 relative to controls. (C) Relative rates (relative fluorescent units/time) of mitochondrial superoxide production in fibroblasts was
measured with the superoxide sensitive probe dihydroethidium in the presence or absence of the complex I inhibitor rotenone. (D) Growth rate
in medium devoid of glucose but containing 5mM galactose and 50 mM sodium azide was normalized to growth rate in basal medium to account
for variation in the baseline growth rate of each cell line. The normalized growth rate in Cases 1 and 2 was significantly lower than controls. (E)
Purified recombinant NAXD protein, without or with missense mutations p.(Gly63Ser) and p.(Arg308Cys), was pre-incubated at the indicated
temperature for 30min prior to addition to a reaction mixture for the spectrophotometric assay of NADHX dehydratase activity. Data are
mean  SD, n4 3 per measurement from at least two independent experiments. Statistical significance was determined using one-way ANOVA
with Bonferroni correction for multiple comparisons; *P5 0.05, **P5 0.01, ***P5 0.001.
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to values induced by a complete loss of function for NAXD
in an experimental cell line (Becker-Kettern et al., 2018).
The levels in Case 3 were only just above the detection
threshold, which may be due to the frameshift mutation
in this patient preventing expression of the mitochondrial
and endoplasmic reticulum targeted NAXD isoforms (early
truncation), but allowing for expression of the cytosolic
NAXD protein from the ATG residing in exon 2 (Met3
in Supplementary Fig. 3). The same reasoning would also
apply to Case 5, for which fibroblasts were, however, not
available for measurements. These results provide strong
support that the NADHX accumulation is specifically
caused by NAXD mutations.
NAD(P)H are essential cofactors for many cellular reac-
tions, particularly in the mitochondria, therefore accumula-
tion of the non-canonical NAD(P)HX derivatives may
impede multiple cellular functions including key mitochon-
drial dehydrogenases (Yoshida and Dave, 1975; Prabhakar
et al., 1998). Subjects with pathogenic variants in NAXE
had decreased complex I activity (Kremer et al., 2016)
indicating impaired mitochondrial function as a conse-
quence of a deficiency in one of the NAD(P)HX repair
enzymes. Respiratory chain activity was impaired in
NAXD patients; fibroblasts had a significant decrease in
the expression of complex I and IV, and activity of com-
plex IV and muscle enzymology showed reduced respira-
tory chain activity (complex II + III, Case 2; complex I,
Case 4; complex I and IV, Case 6). We also demonstrated
reduced superoxide production in NAXD subjects, which
may be explained by decreased expression of specific com-
plex I subunits subsequently affecting holocomplex stabi-
lity, but partial enzyme activity may still remain because of
preservation of NADH oxidation in the matrix arm of
complex I. Mitochondrial dysfunction can also be revealed
by culturing cells under galactose growth conditions
(Robinson et al., 1992) in the presence of the complex IV
inhibitor sodium azide (Swalwell et al., 2011), which limits
ATP production by glycolysis, forcing cells to rely on mito-
chondrial OXPHOS. There was a significant decrease in the
growth rate of fibroblasts from Cases 1 and 2 compared to
control fibroblasts under galactose conditions, further sup-
porting that mitochondrial function in fibroblasts from
NAXD subjects is compromised.
To determine the effect of the NAXD missense variants
[p.(Arg308Cys) and p.(Gly63Ser)] on NADHX dehydratase
activity, the missense variants were introduced by site-direc-
ted mutagenesis into the cytosolic NAXD cDNA since simi-
lar kinetic properties were previously obtained for both
mitochondrial and cytosolic NAXD/Carkd (mouse homo-
logue of human NAXD) (Marbaix et al., 2011) and the
cytosolic protein gave greater yield. Analysis of the kinetic
properties for the two missense variants revealed signifi-
cantly reduced Vmax and increased KM compared to the
wild-type protein. Thermostability analysis revealed loss
of enzymatic activity upon pre-incubation temperatures
above 30C, and the thermolability was more pronounced
for the p.(Arg308Cys) variant. The Gly63 residue is highly
conserved from bacteria to humans (Marbaix et al., 2011);
the Arg308 residue is also conserved in the mouse and
yeast homologs of NAXD, but not in the Escherichia coli
homologue (Marbaix et al., 2011). This arginyl residue is
relatively close to the C-terminus of the protein, as are the
splicing and frameshift mutations found in Cases 1 and 2,
respectively, suggesting that this may be a critical domain
for NAXD protein stability. In addition, the thermolability
of the NAXD missense variants found in Cases 1 and 2
may at least in part explain the coincidence of deterioration
in the subjects sometimes occurring after episodes of fever.
Those individuals who had infections may have had unre-
ported fevers secondary to the viral infection, which likely
precipitated rapid decompensation. In summary, our
in vitro analyses of recombinant NAXD demonstrated
that the missense variants, while retaining residual
enzyme activity, show a markedly decreased stability espe-
cially at higher temperatures.
This report highlights the importance of the NAD(P)HX
repair system to preserve cellular and overall health in
humans. We could show high intracellular NADHX accu-
mulation for three of the four individuals where fibroblast
lines were available for analysis, and impaired mitochon-
drial function. The missense variants found in Cases 1 and
2 led to partial loss of enzyme activity and a significant
decrease in thermostability. More particularly, NAXD defi-
ciency appears to have devastating effects in key tissues
such as the brain, which are critically dependent on efficient
energy metabolism and are exquisitely sensitive to abnor-
mal metabolite accumulation. After 2-hydroxyglutaric acid-
uria (Van Schaftingen et al., 2009) and NAXE deficiency
(Kremer et al., 2016), NAXD deficiency represents now the
third known disorder of metabolite repair. We also suggest
that NAXD deficiency should be included in the growing
list of genetic disorders associated with fever-induced neu-
rological deterioration (Powers and Scheld, 1996; Longo,
2003).
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